TY - JOUR
T1 - Stromal cell-derived factor 1α (SDF-1α)
T2 - A marker of disease burden in patients with atrial fibrillation
AU - Li, Dana
AU - Bjørnager, Louise
AU - Langkilde, Anne
AU - Andersen, Ove
AU - Jøns, Christian
AU - Agner, Bue Fridolin Ross
AU - Dixen, Ulrik
AU - Landex, Nadia L.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Objectives: Stromal cell-derived factor 1a (SDF-1α), is a chemokine and is able to home hematopoietic progenitor cells to injured areas of heart tissue for structural repair. Previous studies have found increased levels of SDF-1α in several cardiac diseases, but only few studies have investigated SDF-1α in patients with atrial fibrillation (AF). We aimed to test SDF-1α in a large cohort of patients with AF and its role as a prognostic marker. Design: Between January 1st 2008 to December 1st 2012, 290 patients with ECG documented AF were enrolled from the in-and outpatient clinics at the Department of Cardiology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark. Plasma levels of SDF-1α were measured using ELISA technique. Clinical data were registered and patient follow-up was conducted. Results: Patients with permanent AF had significantly higher SDF-1α levels (2199.5 pg/ml) than the patients with paroxysmal AF (1982.0 pg/ml) and persistent AF (1906.0 pg/ml), p < 0.0005. Higher SDF-1α level was associated with longer time spent in the hospital per readmission, p < 0.05. Conclusion: In AF patients, a higher SDF-1α level was found in patients with a more progressive state of arrhythmia and was associated with longer hospitalizations. These findings suggest that SDF-1α could prove valuable in risk stratification and evaluating the disease burden in AF patients.
AB - Objectives: Stromal cell-derived factor 1a (SDF-1α), is a chemokine and is able to home hematopoietic progenitor cells to injured areas of heart tissue for structural repair. Previous studies have found increased levels of SDF-1α in several cardiac diseases, but only few studies have investigated SDF-1α in patients with atrial fibrillation (AF). We aimed to test SDF-1α in a large cohort of patients with AF and its role as a prognostic marker. Design: Between January 1st 2008 to December 1st 2012, 290 patients with ECG documented AF were enrolled from the in-and outpatient clinics at the Department of Cardiology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark. Plasma levels of SDF-1α were measured using ELISA technique. Clinical data were registered and patient follow-up was conducted. Results: Patients with permanent AF had significantly higher SDF-1α levels (2199.5 pg/ml) than the patients with paroxysmal AF (1982.0 pg/ml) and persistent AF (1906.0 pg/ml), p < 0.0005. Higher SDF-1α level was associated with longer time spent in the hospital per readmission, p < 0.05. Conclusion: In AF patients, a higher SDF-1α level was found in patients with a more progressive state of arrhythmia and was associated with longer hospitalizations. These findings suggest that SDF-1α could prove valuable in risk stratification and evaluating the disease burden in AF patients.
U2 - 10.3109/14017431.2015.1103892
DO - 10.3109/14017431.2015.1103892
M3 - Journal article
C2 - 26441035
SN - 1401-7458
VL - 50
SP - 36
EP - 41
JO - Scandinavian Cardiovascular Journal, Supplement
JF - Scandinavian Cardiovascular Journal, Supplement
IS - 1
ER -